Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C2H3Cl3O4P.Na |
| Molecular Weight | 251.365 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].OP([O-])(=O)OCC(Cl)(Cl)Cl
InChI
InChIKey=WFKJEZKHPGDCRK-UHFFFAOYSA-M
InChI=1S/C2H4Cl3O4P.Na/c3-2(4,5)1-9-10(6,7)8;/h1H2,(H2,6,7,8);/q;+1/p-1
Triclofos is primarily indicated in conditions like Insomnia, and can also be given in adjunctive therapy as an alternative drug of choice in Nausea, vertigo, labyrinthine disorders. It is also used sedate people suffering from anxiety or tension before medical investigations. Triclofos is converted to Trichloroethanol in the body .This act on brain and produces sleep. Trichloroethanol decreases time taken to fall asleep and lengthen the sleep. Triclofos is most commonly used agent for sedation in
neonates as well as in older infants and children in Japan.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | TRICLOS Approved UseTriclofos is used to treat sleeping problems (insomnia) in people. It is also used sedate people suffering from anxiety or tension before medical investigations. |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
8 h |
1 g single, oral dose: 1 g route of administration: Oral experiment type: SINGLE co-administered: |
TRICLOFOS plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
65% |
1 g single, oral dose: 1 g route of administration: Oral experiment type: SINGLE co-administered: |
TRICLOFOS plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Iatrogenic encephalopathy. | 1970 May |
|
| Comparison of resistance measured by the interrupter technique and by passive mechanics in sedated infants. | 2001 Aug |
|
| A comparative evaluation of oral midazolam with other sedatives as premedication in pediatric dentistry. | 2002 Winter |
|
| A pediatric sedation/anesthesia program with dedicated care by anesthesiologists and nurses for procedures outside the operating room. | 2004 Jul |
|
| Non-epileptic pedaling-like movement induced by triclofos. | 2004 Oct |
|
| Comparison of solvent mixtures for pressurized solvent extraction of soil fatty acid biomarkers. | 2008 Oct 19 |
|
| Proteomic analysis of regenerating mouse liver following 50% partial hepatectomy. | 2009 Dec 29 |
|
| Modeling hydroxyl radical distribution and trialkyl phosphates oxidation in UV-H2O2 photoreactors using computational fluid dynamics. | 2010 Aug 15 |
|
| Procedural sedation analgesia. | 2010 Jan |
Patents
Sample Use Guides
The usual adult dose as a hypnotic is 1 to 2 g orally at night. A suggested hypnotic dose for children 1 month to 1 year of age is 25 to 30 mg/kg; children aged 1 to 5 years may be given single doses of 250 to 500 mg, and children aged 6 to 12 years may be given single doses of 0.5 to 1 g.
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29756
Created by
admin on Fri Dec 15 15:35:50 GMT 2023 , Edited by admin on Fri Dec 15 15:35:50 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB15606MIG
Created by
admin on Fri Dec 15 15:35:50 GMT 2023 , Edited by admin on Fri Dec 15 15:35:50 GMT 2023
|
PRIMARY | |||
|
DBSALT001424
Created by
admin on Fri Dec 15 15:35:50 GMT 2023 , Edited by admin on Fri Dec 15 15:35:50 GMT 2023
|
PRIMARY | |||
|
23677832
Created by
admin on Fri Dec 15 15:35:50 GMT 2023 , Edited by admin on Fri Dec 15 15:35:50 GMT 2023
|
PRIMARY | |||
|
m11090
Created by
admin on Fri Dec 15 15:35:50 GMT 2023 , Edited by admin on Fri Dec 15 15:35:50 GMT 2023
|
PRIMARY | Merck Index | ||
|
230-652-3
Created by
admin on Fri Dec 15 15:35:50 GMT 2023 , Edited by admin on Fri Dec 15 15:35:50 GMT 2023
|
PRIMARY | |||
|
CHEMBL1201317
Created by
admin on Fri Dec 15 15:35:50 GMT 2023 , Edited by admin on Fri Dec 15 15:35:50 GMT 2023
|
PRIMARY | |||
|
DTXSID60993262
Created by
admin on Fri Dec 15 15:35:50 GMT 2023 , Edited by admin on Fri Dec 15 15:35:50 GMT 2023
|
PRIMARY | |||
|
7246-20-0
Created by
admin on Fri Dec 15 15:35:50 GMT 2023 , Edited by admin on Fri Dec 15 15:35:50 GMT 2023
|
PRIMARY | |||
|
9F90KA5Q8U
Created by
admin on Fri Dec 15 15:35:50 GMT 2023 , Edited by admin on Fri Dec 15 15:35:50 GMT 2023
|
PRIMARY | |||
|
104696
Created by
admin on Fri Dec 15 15:35:50 GMT 2023 , Edited by admin on Fri Dec 15 15:35:50 GMT 2023
|
PRIMARY | RxNorm | ||
|
100000077273
Created by
admin on Fri Dec 15 15:35:50 GMT 2023 , Edited by admin on Fri Dec 15 15:35:50 GMT 2023
|
PRIMARY | |||
|
C66630
Created by
admin on Fri Dec 15 15:35:50 GMT 2023 , Edited by admin on Fri Dec 15 15:35:50 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
